ArticleCell death discovery2026
USP21 functions as an oncogenic regulator of the Mdm2-p53 axis in colorectal cancer.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of USP19 in human diseases: from molecular function to clinical relevance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The tumor suppressor p53 is a pivotal guardian against tumorigenesis, with its activity primarily constrained by the ubiquitin E3 ligase Mdm2. However, the full complexity of the Mdm2-p53 regulatory network remains elusive. Here we report that the deubiquitinating enzyme USP21 physically interacts with and stabilizes Mdm2 in a deubiquitinase activity-independent manner. Mechanistically, USP21 acts as a scaffold to facilitate the USP7-Mdm2 interaction, enhancing Mdm2 stability and consequently promoting p53 ubiquitination and degradation. Functionally, USP21-mediated p53 suppression attenuates its tumor suppressive activity and accelerates colorectal cancer progression. Clinically, USP21 is upregulated in colorectal cancer tissues, and its elevated expression correlates with poor overall survival in patients with wild-type p53 tumors, but not in those with p53 mutations. These findings establish USP21 as an important regulator of the Mdm2-p53 axis and reveal its critical role in promoting colorectal carcinogenesis via p53 inhibition.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.